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ABSTRACT
Objective: Chronic obstructive pulmonary disease
(COPD) is a major health problem with high societal
costs. The Global Initiative for Chronic Lung Disease
(GOLD) has identiﬁed a need for health economics data
for COPD. For chronic diseases, such as COPD, where
the natural history of disease is lifetime, a modeling
approach for economic evaluation may be more realistic
than prospective, piggy-backed clinical trials or speciﬁc
COPD cohort studies. Simulation models can be used to
extrapolate clinical data beyond the limited time frame
of clinical trials, to analyze subgroups of patients or to
explore uncertainty regarding the results by using sensi-
tivity analysis techniques. Our purpose has been to
develop a ﬂexible computer simulation model for COPD
that will represent disease progression and GOLD recom-
mendations, useful for economic evaluations of new med-
icines to meet the needs of various payer requirements for
reimbursement and resource allocation.
Methods: This article describes a two-dimensional
Markov model, which uses data from multiple sources
about disease progression, exacerbation frequency and
duration, mortality, costs, burden of illness, and the rela-
tionships between those variables. The model is evaluated
using stochastic uncertainty analysis, it allows compari-
son of treatments affecting different disease mechanisms,
and it uses primary data validated against published
sources.
Results: We have evaluated two hypothetical interven-
tions treating different features of the disease (lung func-
tion decline and acute exacerbations). These analyses
show that reducing lung function decline must be a long-
term strategy compared to reducing the number of
exacerbations. It was necessary to have a long term like
30 years, with 10,000 patients and 20% increase in price,
or 20 years with equal prices to show cost-effectiveness
with statistical signiﬁcance for a treatment that reduces
lung function decline.
Conclusions: Our study shows the value of modeling as a
tool for evaluating different scenarios and for combining
several sources of data, to provide estimates that would
otherwise be unavailable. Clinical trials of this size and
duration would be unrealistic.
Keywords: COPD, chronic bronchitis, costs, disease
model, Markov, simulation.
1. Introduction
Chronic obstructive pulmonary disease (COPD) is
an overall term for a number of related respira-
tory conditions, including chronic bronchitis and
emphysema. It is a progressive, irreversible disease
with an increasing degree of airﬂow limitation. In
later stages, patients with COPD have a poor qual-
ity of life owing to the reduction in lung function
and periods of acute worsening of the disease (exac-
erbations). The most common cause of COPD is
cigarette smoking. COPD is the fourth leading
cause of death in the world [1]. In 1990 it was
ranked as the 12th leading cause of disability-
adjusted life-years lost and, according to projec-
tions, it will become the ﬁfth such cause in 2020 [2].
COPD is a disease with substantial societal costs
[3–5]. The distribution of costs is skewed. The most
expensive 20% of patients with COPD account for
74% of health-care costs [5]. The costs have two
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important determining factors: poor lung function
[3,6] and exacerbations [7–9]. One study has shown
that exacerbations explain almost half of the costs
of COPD [7].
The Global Initiative for Chronic Lung Disease
(GOLD) was established in 1997. Its goals are to
increase awareness of COPD and decrease morbid-
ity and mortality from the disease. One issue raised
by the GOLD Panel is the lack of economic infor-
mation concerning COPD and its treatment options
[10]. Thus, our purpose has been to create a ﬂexible
computer simulation model for COPD that will rep-
resent disease progression and GOLD recommenda-
tions. Ultimately, the model may be useful for
economic evaluations of new medicines to meet the
needs of various payer requirements for reimburse-
ment and resource allocation. This article describes
the model, together with an example of how it can
be used—an evaluation of the difference in costs
and effectiveness of two hypothetical interventions
treating different mechanisms of the disease: irre-
versible lung function decline and exacerbation fre-
quency.
2. Materials and Methods
2.1. Model Structure
COPD is a complex disease. Nevertheless, for the
development of a simulation model, the natural his-
tory of COPD can be simpliﬁed to manifest itself in
two principle ways: the patient has an irreversible
decline in lung function, combined with periods of
exacerbations, and those factors affect each other. It
has been shown that decreased lung function
increases the risk of exacerbations [7,11]. There may
also be reason to believe that exacerbations cause a
permanent reduction in lung function [12,13]. This
is the background to a two-dimensional Markov
model, which uses data from multiple sources about
decline in lung function, exacerbation frequency and
duration, mortality, costs, burden of illness, and the
relationships between those variables. Table 1 sum-
marizes the different sources of information used to
populate the model.
We use a two-dimensional Markov chain to rep-
resent disease severity and exacerbation status.
Each dimension is in itself a Markov chain, with a
separate state space. Figure 1 shows the possible
events in the model. The current disease severity
box represents the current state of the disease sever-
ity chain. This chain is updated mid-yearly, to a
lesser or worse severity or to death. The transition
rates to worse severity and death may be increased
depending on model variables and recent exacerba-
tion experience. The ﬁgure is drawn with focus on
the current disease severity, regardless of which
severity it currently represents. Inside the current
disease severity box the exacerbation status chain is
shown, which is updated weekly. The rates of exac-
erbations depend on disease severity. Together, the
two dimensions describe the health status of a
patient in the model at any given time. The health
status of a patient depends on his or her previous
health status, age, variables speciﬁc to disease
assumptions, and variables speciﬁc to the interven-
tion under study.
2.2. Disease Progression and Exacerbation 
Framework
2.2.1. Health State Structure and Transition
Probabilities for Disease Severity Disease severity
is deﬁned by lung function (forced expiratory vol-
ume in the ﬁrst second, FEV1, as a percentage of the
predicted normal value, PN), and divided into four
different states as deﬁned by the GOLD guidelines
(I, FEV1 ≥ 80% of PN; IIA, 50% £ FEV1 < 80% of
PN; IIB, 30% £ FEV1 < 50% of PN; III,
FEV1 < 30% of PN) [14].
Figure 2 depictis the model with respect to dis-
ease severity and is described in detail below. We
Table 1 Information sources for the different variables in the model
Variable Source
Disease progression and mortality A 10-year follow-up study of  patients in northern Sweden (section 2.2.1)
Exacerbation frequency and duration for patients in GOLD 
states IIA, IIB, III 
A 5-year chart review study of  patients in London (section 2.2.2)
Exacerbation frequency and duration for patients in GOLD 
state I 
Modeling based on expert opinion partly informed by a 5-year chart review 
study of  patients in London (section 2.2.2) and cost-of-illness and cost-of-
exacerbation studies in northern Sweden (section 2.3).
Inﬂuence of  exacerbations on disease progression (alpha) Expert opinion partly informed by studies (section 2.2.3)
Inﬂuence of  exacerbations on mortality (beta) Expert opinion partly informed by studies (section 2.2.4)
Cost tariffs for each COPD severity state A cost-of-illness study in northern Sweden (section 2.3)
Cost of  exacerbations A cost-of-exacerbation study in northern Sweden (section 2.3)
QALY weights at each disease severity state
QALY weights during exacerbations
A cost-of-illness study in northern Sweden (section 2.3)
Expert opinion partly informed by a study of  asthma in the UK (section 2.3)
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made a number of assumptions about the transition
probabilities so that the model would approximate
COPD disease history.
1. Patients can remain in their current health state.
Because the progress of the disease is very slow,
this should be the typical behavior.
2. Patients may progress to the next worse health
state as shown by the downward-pointing
arrows in Figure 2. With a sufﬁciently short
cycle length (i.e., 1 year), there should be no
need to allow transitions directly to further
worse states (e.g., from I to IIB). This means
that we have transitions between only adjacent
severities.
3. Patients can regress to the next milder health
state as shown with upward-pointing arrows
in Figure 2. This represents short-term ﬂuctua-
tions in lung function. We do not allow
patients who have regressed one step to regress
even further, because this would violate the
common belief of the disease history. We there-
fore have two states describing IIA (2 and 3)
and two states describing IIB (4 and 5). Apart
from states 3 and 5 being closed to further
regressions, states 2 and 3 are identical, as are
states 4 and 5.
4. Finally, every health state allows a transition to
death.
To populate the model with disease progression
transition probabilities, we needed to investigate the
natural development of the disease in COPD
patients. The Obstructive Lung Disease in Northern
Sweden (OLIN) studies had the relevant data for
this purpose. OLIN is a large-scale research project
on the epidemiology of COPD and type 1 allergy in
Northern Sweden [15–17]. Studies included in this
project provided 10-year follow-up data per subject
on FEV1 as a percentage of the predicted value for
1457 subjects born in 1919 to 1920, 1934 to 1935,
and 1949 to 1950. The subjects were not taken off
their usual medicine before being measured. There-
fore, their FEV1 resembles a prebronchodilator
FEV1 apart from usual medicine still being present.
This is closer to a real-life measurement. As the
GOLD guidelines use postbronchodilator FEV1 to
deﬁne COPD severity, there is a discrepancy. The
effect of the discrepancy is that our FEV1 measure-
ments are somewhat lower, at most some percent-
ages (3%-7%) according to a number of studies.
Computing the FEV1% of predicted value will,
however, reduce the difference. We will return to
this in the discussion. The patients were classiﬁed
into the GOLD states I, IIA, IIB, and III and death
in 1986 and 1996. Sixty patients went to a milder
state over 10 years, 56 patients moved from IIA to
I, 3 patients from IIB to IIA, and 1 patient from III
to IIB. As described above, assumption 3 allows dis-
ease regression to some extent.
On the basis of the assumptions 1 through 4
described above and the classiﬁcation of patients at
the beginning and end of the 10-year period; the
transition probabilities were estimated in each of
the three age groups. Exact probabilities cannot be
presented here, as they will be published by OLIN.
One-year cycles were used for the disease progres-
Figure 1 Overview of  the model. The outer box represents the cur-
rent disease severity. General risks associated with the disease severity
are shown as arrows starting with circles. The inner boxes represent
exacerbation states within the current disease severity. Time with
exacerbation increases the risk of  disease progression (depending on a
variable alpha) and death (depending on beta). The outer box repre-
sents any of  boxes 1 through 6 in Figure 2.
Mild
exacerbation
Moderate 
exacerbation
Severe
exacerbation
Move to a milder disease severity
Move to a worse disease severity
Increases the risk of moving 
to a worse disease severity (a)
DeathIncreases the 
risk of Death (b)
Current disease severity
Exacerbation-
free
Figure 2 States structure and transitions for disease severity. The
typical pattern of  disease progression would be to move from 1 to 2,
4, 6, and then 7. Nevertheless, also built into the model is the possi-
bility of  regressing one step in the disease, that is, to temporarily move
into a milder disease state (states 1, 3, and 5). From these it is not pos-
sible to regress further.
Death
III
IIB
IIA
I 1
2
4
6
7
3
5
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sion Markov chain. Using the resulting estimates for
the three age groups, probabilities for any given age
(minimum 36.5 years) are estimated using linear
interpolation, as described in Appendix 1.
These probabilities include all-cause mortality,
disease progression and disease regression. The
mortality estimates were compared to the death
rates in 1996 of the general Swedish population
[18]. Patients with COPD states I and IIA were sim-
ilar to the general population, whereas patients with
COPD states IIB and III had higher mortality, about
twice as high for state IIB and roughly ﬁve times as
high for state III (data on ﬁle).
2.2.2. State Structure and Transition Probabilities
for Exacerbation Status The second dimension in
the model is exacerbation status, which is
exacerbation-free, mild, moderate, or severe. We
assume that the patient returns to exacerbation-free
after each exacerbation, as shown in Figure 3. A
mild exacerbation that develops into a moderate
exacerbation will be regarded as a moderate exac-
erbation, and a moderate exacerbation that devel-
ops into a severe one will be regarded as severe in
the model framework.
We use a symptom-driven deﬁnition of exacerba-
tions from Seemungal et al. [12]: an increase in any
two “major” symptoms (dyspnea, sputum puru-
lence, sputum amount) or an increase in one
“major” and one “minor” symptom (wheeze, sore
throat, cough, and symptoms of a common cold,
which were nasal congestion/discharge) for at least
2 consecutive days.
There is a strong relationship between exacer-
bation severity and costs [7,19], and it is therefore
important to differentiate between exacerbations of
different severity in a computer simulation model.
For this, we have used a resource-driven staging
developed from Rodriguez-Roisin [20]:
• Mild, if the patient can manage in his or her
normal environment, including phone calls to a
doctor that might be followed by a course of
antibiotics or oral steroids;
• Moderate, if the patient must make an unsched-
uled visit to the doctor; or
• Severe, if the patient requires hospitalization or
emergency room visit.
A cost value is assigned to each level of severity.
Data on exacerbation frequency and duration
were taken from a study by Donaldson et al. [21],
where diary cards from 133 COPD patients (31 in
state IIA, 62 in state IIB, and 40 in state III), fol-
lowed for an average of 3 years (1–5 years), were
studied to analyze the frequency and duration of
exacerbations of three levels of severity in moder-
ate and severe COPD patients. See Seemungal et
al. [12] for a more detailed description of these
patients. Seemungal et al. showed that a propor-
tion of the exacerbations were not reported as
such to the clinician. These are per deﬁnition mild
exacerbations and have been included in our esti-
mated frequencies. The duration of an exacerba-
tion was the time until the symptom scores
returned to the run-in average; over days 14 to 7
before the start of exacerbation. The frequency
and duration of exacerbations depending on dis-
ease severity and exacerbation severity are shown
in Table 2, and the corresponding transition prob-
abilities, in Table 3.
Exacerbation frequency is positively related to
disease severity. The ﬁgures are slightly higher than
those of Anthonisen et al. [22], who found 1.2 mod-
erate to severe exacerbations per year among mild
patients, and Dewan et al. [23], who found 1.1
moderate to severe exacerbations per year among
all COPD patients who had had at least one exac-
erbation. This is probably due to the superior study
design of Donaldson et al. [21], where patients areFigure 3 State structure and transitions for the exacerbation status.
MildNone Moderate Severe
4
2
31
Table 2 Average frequency and duration of  exacerbations*
Exacerbation type 
Mild Moderate Severe
Number of  exacerbations per year depending on disease severity
I 0.05 0.07 0.01
IIA 1.01 1.31 0.14
IIB 1.06 1.45 0.17
III 1.47 1.72 0.33
Duration (days) depending on disease severity
I 12.64 12.55 4.67
IIA 12.64 12.55 4.67
IIB 12.64 14.06 8.49
III 10.20 12.58 8.33
*At model evaluation, these are sampled from the empirical distributions.
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Table 3 Average weekly transition probabilities for exacerbation status*
From state
To state
Exacerbation-free Mild Moderate Severe
GOLD I
Exacerbation-free 0.9975 0.0011 0.0014 0.0001
Mild 0.5538 0.4462 0.0000 0.0000
Moderate 0.5576 0.0000 0.4424 0.0000
Severe 1.0000 0.0000 0.0000 0.0000
GOLD IIA
Exacerbation-free 0.9497 0.0211 0.0273 0.0019
Mild 0.5538 0.4462 0.0000 0.0000
Moderate 0.5576 0.0000 0.4424 0.0000
Severe 1.0000 0.0000 0.0000 0.0000
GOLD IIB
Exacerbation-free 0.9434 0.0224 0.0306 0.0036
Mild 0.5537 0.4463 0.0000 0.0000
Moderate 0.4979 0.0000 0.5021 0.0000
Severe 0.8244 0.0000 0.0000 0.1756
GOLD III
Exacerbation-free 0.9245 0.0315 0.0369 0.0071
Mild 0.6865 0.3135 0.0000 0.0000
Moderate 0.5565 0.0000 0.4435 0.0000
Severe 0.8400 0.0000 0.0000 0.1600
*At model evaluation, these are sampled from the empirical distributions.
good at reporting exacerbations and recall bias is
avoided.
The duration of exacerbations follows a distinc-
tive pattern, where severe exacerbations are shorter
than the mild and moderate ones. This may be due
to mortality in connection with exacerbation or bet-
ter-treated patients in hospitals speeding up recov-
ery or possibly that the symptoms had already
begun to get worse during the run-in period. The
reasons for this are being investigated, but our cur-
rent hypothesis is that more severe patients experi-
ence more exacerbations and therefore know to
seek medical attention earlier. They are therefore
able to bring their exacerbations to an end faster by
dealing with them earlier. The duration of severe
exacerbations in the study by Donaldson et al. is
similar to the length of hospitalization owing to
COPD exacerbations found in other studies: 6.2 to
10 days [8,9,24–26]. Miravitlles et al. [11] found a
higher risk of hospitalization with decreasing FEV1,
similar to the data of Donaldson et al.
No data were available about the frequency and
duration of exacerbations of different severity
among patients in GOLD I. We therefore assumed
that GOLD I and IIA have the same relative fre-
quencies of exacerbation types. We also assume that
the societal costs in these groups are completely
attributable to exacerbations, that is, no ﬁxed costs.
This is not unlikely for state IIA, where the esti-
mated societal cost per year for exacerbations (SEK
6018, recalculated according to GOLD classiﬁca-
tion from study databases in [3,7]) (SEK 1 = EURO
0.1087 on January 20, 2003) closely matches the
estimated total societal cost of COPD per year (SEK
5810). On these assumptions, the exacerbation
costs in GOLD I would add up to a total societal
cost of SEK 1027 in 1 year. We therefore estimated
the GOLD I exacerbation rates from the GOLD IIA
rates, multiplied by the ratio of GOLD I to GOLD
IIA societal costs (Table 4), on average 1,027/
18,866 ª 0.0544. The prevalence-weighted fre-
quency of exacerbations of all types then becomes
1.27 per patient and year, which is in line with pub-
lished data [22,23]. The durations in GOLD I are
assumed to be the same as those in IIA.
The set of transition probabilities that needs to
be estimated consists of the weekly probabilities of
beginning and ending a mild, moderate, and severe
exacerbation. The frequency of exacerbations de-
pends on the level of lung function [11], and sepa-
rate sets of transition probabilities were estimated
for each severity grade of COPD. These are shown
in Table 3. The estimation method is described in
detail in Appendix 1. Exacerbations last on average
4.7 to 14.1 days depending on type and GOLD clas-
siﬁcation (Table 2). Our choice of cycle length for
the exacerbation status Markov chain is 1 week,
which gives reasonable accuracy in computing time
spent with exacerbation.
2.2.3. Exacerbation Status Inﬂuences Disease
Progression Exacerbations inﬂuence disease pro-
gression [13], although to what extent is a current
area of research. To compensate for limited knowl-
edge of this dependence, we have designed a simple
mechanism for it. The mechanism is controlled by a
Borg et al.158
variable, alpha, ranging from 0 to 1, where a value
of 0 means independence between disease progres-
sion and exacerbations, whereas a value of 1 means
that disease progression is completely caused by
exacerbations, that is, cannot take place unless an
exacerbation has taken place.
When a patient is simulated, independence
between disease progression and exacerbations
means that the risk of disease progression is con-
stant for a given patient. When disease progression
is completely caused by exacerbations, the risk of
disease progression may vary for a given patient,
depending on recent exacerbation experience.
Having had no recent exacerbations leads to a zero
risk, whereas each recent exacerbation increases the
risk.
Values of alpha in between represent weighted
mixtures of the previous two scenarios. Data on dis-
ease progression in connection with exacerbations
are scarce, but Donaldson et al. [13] have examined
a sample of moderate and severe patients. Using this
as a basis for discussion, we have chosen a default
value of a = 0.25, that is, a limited dependence
between progression and exacerbations.
2.2.4. Exacerbation Status Inﬂuences Mortality
Many COPD-related deaths occur as a consequence
of severe exacerbations [8,26,27]. There is consen-
sus about the existence of this dependence,
although not about its extent. Accordingly, by anal-
ogy with the alpha mechanism in the previous sec-
tion, we use a simple mechanism to allow for this
inﬂuence. The inﬂuence of exacerbations on mor-
tality is controlled by a variable, beta (0–1), by
analogy with the alpha mechanism, with one excep-
tion: only severe exacerbations inﬂuence mortality
(see Appendix 1). Calibration of the model shows
the best ﬁt when b = 0.3. This value gives a model
mortality rate during severe exacerbations for
severe patients of 11.19%, compared with 11% as
seen in Connors et al. [8], and a mortality in con-
nection with a severe exacerbation for a prevalence-
weighted group of COPD patients with
FEV1 < 80% predicted at 4.87%, compared with
4% as seen in Mushlin et al. [26].
2.3. Cost  and  Burden  of   Illness 
A cost-of-illness study was performed in collabora-
tion with the OLIN studies [3]. Table 4 shows the
costs from this study recalculated according to the
GOLD division into severity states of the disease.
The cost of exacerbations was taken from a study
carried out in collaboration with the OLIN studies
[7]. To ﬁt the division of exacerbation severity used
in the model, we have put together the two mildest
exacerbation type classes from the exacerbation
cost study to form one (see Table 4).
Non-exacerbation-related costs were estimated
by subtracting exacerbation-related costs, com-
puted from exacerbation costs per occurrence and
exacerbation rates, from the costs per year, and they
are shown as base costs in Table 4.
The respondents in the cost-of-illness study were
asked to complete the EQ-5D quality-of-life ques-
tionnaire, from which quality-adjusted life-years
(QALYs) weights were estimated according to the
UK EQ-5D index tariff [28]. The QALY weights for
each COPD severity state estimated from these
data, recalculated to GOLD states with data from
Ståhl et al. [29], are shown in Table 4.
There were no available data on QALY weights
during exacerbations. We have therefore assumed a
percentage change in the reduction from the
patient’s original QALY weight. The size of this
Table 4 Average variable values*
COPD severity Exacerbation severity 
I IIA IIB III Mild Moderate Severe
Base cost (SEK/week) Cost per occurrence (95% CI)
Health-care cost 10  0  300 1,320 191
(98–289)
2111
(1673–2612)
21,852 
(14,436–29,825)
Societal cost 10  150  740 3,380 294
(123–525)
5814
(2748–9788)
21,852 
(14,436–29,825)
Total cost (SEK/year)
Health-care cost 849 5810 19,455 79,836
Societal cost 1027 18,866 47,666 193,402
QALY weight when exacerbation-free
QALY weights at exacerbations, expressed as a fraction of  
the exacerbation-free weight by COPD severity
QALY weight U
Mean 0.8971 0.7551 0.7481 0.5493 U ¥ 0.95 U ¥ 0.85 U ¥ 0.30
SD 0.1117 0.2747 0.2991 0.3129
*Costs are expressed in SEK, 1999. SEK 1 = 0.1087€ on January 20, 2003. At model evaluation, costs and QALY weights are sampled from the empirical distributions.
Sources: Jansson et al. [3] and Andersson et al. [7,30]. Total costs recalculated from Jansson et al. [3] to ﬁt GOLD severities. Base (non-exacerbation-related) costs are
rounded to 10 SEK.
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decrease is dependent on the severity of the exacer-
bation, as follows:
• Mild exacerbation, 5% (assumption by expert
panel: J. Wedzicha, A. Gulsvik, and S.D. Sulli-
van);
• Moderate exacerbation, 15% (assumption by
expert panel: J. Wedzicha, A. Gulsvik, and S.D.
Sullivan);
• Severe exacerbation, 70% (derived from
asthma data [30]. A survey was made of 100
persons with asthma in the UK, in which their
health-state preference values were measured
on a rating scale. A severe asthma exacerbation
in this study was judged by the expert panel to
be equivalent to a severe COPD exacerbation as
deﬁned in this model.)
2.4. Evaluation Method
The results of a model are most useful if the uncer-
tainty in inputs and assumptions are taken into
account in a systematic way. There is a range of
methods to deal with the uncertainty associated
with a model [31]. The majority of the current
model’s data sources are random samples of indi-
vidual data, and it is therefore bootstrapped [32].
The variable values shown in Tables 2 through 4 are
point estimates from various studies; these studies
are resampled in the bootstrap procedure.
The model can evaluate a base case or compare
two cases, both of which can be interventions. The
base case reﬂects current COPD management
according to the data sources used to populate the
model. Analysis of the base case produces estimates
of costs and outcomes for the speciﬁed patient
group. Comparisons of an intervention with the
base case and comparisons of two interventions
both produce estimates of costs and outcomes of
each case. In addition, the marginal cost associated
with the gain in effectiveness is presented.
2.5. Variables under the User’s Control
The user of the model can control several variables
to deﬁne the patient population, one or two inter-
ventions, and disease assumptions and to make
methodologic choices.
The initial distribution of patients between the
disease severity groups is used to deﬁne which
patient population to evaluate. Regardless of ini-
tial disease severity, all patients start without an
exacerbation. The starting age is given as a single
value or an interval (limits, 36.5–76.5 years). The
time frame is given as a number of years (one or
more).
A societal or health-care provider perspective
and the following effectiveness variables can be cho-
sen: life-years, time without exacerbation, number
of exacerbations, and QALYs. Interventions (one or
two) are deﬁned by reduction in disease progression
risk, reduction in the number of exacerbations,
reduction in duration or severity of exacerbations,
or combinations of those and unit cost (e.g., drug
price).
Assumptions of how disease progression and
mortality are dependent on exacerbations are
deﬁned using alpha and beta. By default, alpha is
0.25 and beta is 0.3.
A 3% discount rate has been set as default in the
model, as recommended by the US Public Health
Service Panel on Cost-Effectiveness in Health and
Medicine [33], but can be changed by the user of the
model. It is also possible to choose different dis-
count rates on costs and effectiveness, as this has
been requested by, for example, NICE [34]. The
number of simulated patients can be chosen, and
this affects the precision of the model. The default
number is 2000 patients, which should provide suf-
ﬁcient precision.
The random seed deﬁnes the sequence of pseudo-
random numbers used for simulation. These
sequences appear completely random for all practi-
cal purposes. The model has been developed using
the software Splus 2000 Professional, Release 3,
2000, running under Windows 2000 Workstation
Professional Build 5.00 SP3, 2002.
3. A Comparison of  Two Treatment 
Strategies for COPD
Smoking cessation has been shown to have bene-
ﬁcial effects on the rate of decline in FEV1 [35].
In patients with COPD, the decline in FEV1
among sustained quitters was only half the rate
as among smokers [36]. Smoking cessation will
also have an impact on other smoking-related dis-
eases, such as cardiovascular disorders and lung
cancer. Unfortunately, the effectiveness of smok-
ing cessation therapies is low. For example, a nic-
otine transdermal patch results in a quitting rate
of 5% with limited support and 6% with inten-
sive support [37].
At present, the only effective way to impact the
progression of COPD is to stop smoking. No drugs
with a long-term effect on FEV1 decline have yet
been developed [38]. This is the ultimate goal of
drug development, because a change in FEV1
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decline would also indicate that the drug affects
the underlying disease mechanisms. It has been
shown that FEV1 is the best variable to show this
[39].
There is a complex relationship between FEV1
decline and exacerbation frequency, which is partly
taken care of in this model. Smoking cessation and
some drugs has at least in part an effect on both
mechanisms. Nevertheless, to illustrate the mecha-
nisms one by one and how they work in the model,
we have analyzed the societal effect of a hypothet-
ical drug treatment with an effect on lung function
reduction that would be similar to that of smoking
cessation, roughly a halving of FEV1 decline (Treat-
ment A), with a hypothetical treatment, similar to
the best existing drugs, which can reduce exacerba-
tions by about 25% [40,41] (Treatment B). What
time perspective would be necessary for a treatment
affecting long-term FEV1 to make it more cost-
effective than a treatment reducing the number of
exacerbations? The example is chosen to highlight
the two dimensions of the model and to show that
different types of therapies can be compared, also
hypothetical treatments.
The following assumptions have been used in the
base case analysis: Treatment A has no direct effect
on exacerbations, but slows down disease progres-
sion by 50%, affecting the lung function decline.
The price per year is SEK 9600 (1044€). Treatment
B has no direct effect on lung function decline, but
reduces exacerbations by 25%. The price per year is
SEK 8000 (870€). We have used a price for Treat-
ment A that is 20% higher than that of Treatment
B, because it would be a ﬁrst-in-class drug, thereby
likely to have a higher price than existing drugs on
the market. The drugs are used in a representative
COPD population with FEV1 < 80% predicted
(GOLD states IIA, IIB, and III). We have used a dis-
count rate of 3% and assumed that a = 0.25 and
b = 0.3. We have evaluated 10,000 patients in anal-
yses over 5, 10, 20, and 30 years. The results are
shown in Table 5.
With the given price difference, 30 years was
needed for Treatment A to become cost-effective
compared to Treatment B. Lengthening the perspec-
tive from 5 to 30 years, societal costs turned from
being signiﬁcantly lower for Treatment B to signif-
icantly higher. The difference in QALYs became sig-
niﬁcant only after 30 years. The difference in utility
values between disease states is rather small in
COPD [29], and therefore the model is relatively
insensitive to changes in QALYs. The annual differ-
ence in societal costs was reduced from SEK 2830
(308€) per person and year with a 5-year perspec-
tive to SEK 716 (78€) with a 30-year perspective.
Thus a perspective of 30 years is needed to make it
worthwhile to reduce lung function decline as much
as smoking cessation would do at a 20% increase in
Table 5 Cost-effectiveness of  Treatments A and B*
Treatment A: halving
FEV1 decline
Treatment B: 25% reduction
of  exacerbations Difference
Lower 95%
limit
Upper 95%
limit
Base case SEK 9600 SEK 8000
5 years
QALYs 3.47 3.47 0.00 -0.02 0.01
Societal costs 166,246 152,098 14,148 10,278 18,205
10 years
QALYs 6.33 6.35 -0.01 -0.05 0.03
Societal costs 294,772 284,852 9,920 2,587 17,468
20 years
QALYs 10.38 10.34 0.04 -0.04 0.12
Societal costs 476,362 488,747 -12,385 -24,544  970
30 years
QALYs 12.44 12.27 0.17 0.05 0.29
Societal costs 584,267 605,756 -21,490 -35,563 -6,757
Equal prices SEK 8000 SEK 8000
5 years
QALYs 3.47 3.47 0.00 -0.02 0.01
Societal costs 158,712 152,098 6,614 2,745 10,671
10 years
QALYs 6.33 6.35 -0.01 -0.05 0.03
Societal costs 280,768 284,852 -4,084 -11,417 3,464
20 years
QALYs 10.38 10.34 0.04 -0.04 0.13
Societal costs 452,031 488,747 -36,716 -48,876 -23,361
30 years
QALYs 12.44 12.27 0.17 0.05 0.29
Societal costs 552,320 605,756 -53,436 -67,509 -38,703
*Costs are expressed in SEK. SEK 1 = 0.1087€ on January 20, 2003.
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treatment cost, compared with reducing the number
of exacerbations to the same extent as existing
drugs.
A sensitivity analysis was made with identical
prices for the two treatment alternatives (SEK
8000) and with time perspectives of 5, 10, 20,
and 30 years. Again, only after 30 years was the
difference in QALYs statistically signiﬁcant. With
equal prices for the two treatment alternatives,
Treatment B had lower societal costs with a time
perspective of 5 years. Nevertheless, when
increasing the analysis to 20 years, Treatment A
had signiﬁcantly lower societal costs than Treat-
ment B.
These analyses show that reducing lung function
decline for COPD patients must be a long-term
strategy compared to reducing the number of exac-
erbations. Here, it was necessary to have a long
term like 30 years, with 10,000 patients and 20%
increase in price or 20 years with equal prices to
show cost-effectiveness with statistical signiﬁcance
for a treatment that reduces lung function decline.
This shows the potential value of modeling, because
clinical trials of this size and duration would be
unrealistic.
4. Discussion
For chronic diseases such as COPD, where the
required study duration could be several years, a
modeling approach may be more realistic than pro-
spective studies. Models of this kind can be used to
extrapolate clinical data beyond the trial, to analyze
subgroups of patients, and to explore uncertainty
regarding the results by using sensitivity analysis
techniques. A modeling approach has been used
earlier to guide policy decisions in chronic diseases
such as Alzheimer’s disease [42], coronary heart
disease [43,44], hypertension [45], and asthma
[46,47].
This article describes a two-dimensional Markov
model for COPD. As an example of how it can be
used, we have evaluated the difference in costs and
effectiveness of two hypothetical interventions
treating different mechanisms of the disease: lung
function development and exacerbation frequency.
The example analyzed shows the value of computer
simulation models, where timelines can be long and
variables can be changed to ﬁnd breakpoints where
therapies are cost-effective. In the current example,
it was shown that more than 20 years of treatment
was needed for the disease development treatment
strategy (Treatment A) to be cost-effective com-
pared to the exacerbation-reducing alternative
(Treatment B) at equal prices.
A Consensus Conference on Guidelines on Eco-
nomic Modeling in Health Technology Assessment
took part at the University of Shefﬁeld, UK, in
1999, with the objective of identifying the proper-
ties of a good decision analytic model. A consensus
statement was published after the conference [48],
summarizing certain characteristics of a good deci-
sion-analysis model. The present model possesses
these characteristics, as described below.
To reduce the overall complexity, we have aimed
for simplicity. Thus, more sophisticated methods
could have been used for some problems, probably
marginally improving the results but increasing
complexity. Nevertheless, the value of a model is
closely related to how transparent it is, and to
review the model, one must become familiar both
with all its components and with the model overall.
By keeping the components simple, the model over-
all will hopefully be transparent enough to allow
critical assessment.
When constructing a model of a complex disease,
different data sources are used and many assump-
tions are made. We have tried to use the most reli-
able data sources, with the decision constraint that
we needed individual data owing to the evaluation
method. Hence, we also needed to collect our own
data in most cases. For validation reasons, we have
tried to have these data published as far as possible
and have also compared them with other published
sources, with satisfactory results.
For some aspects of COPD, we could neither ﬁnd
data nor collect them ourselves, and we had to
make assumptions. These aspects are as follows:
The inﬂuence of exacerbations on disease progres-
sion (alpha) and on mortality (beta). No data could
be found on this, so we created mechanisms under
the user’s control through alpha and beta, to offer a
range of possible types of inﬂuences. QALY weights
sensitive to exacerbation status could not be found.
We had weights for only the disease severity
degrees. Partly informed by data as described ear-
lier, we assumed offsets from the latter weights to
account for exacerbation status.
Exacerbation rates in the mildest group (GOLD
I), had to be estimated with GOLD IIA rates as
described earlier. This assumption is a weakness,
but because these patients are not of major interest
and their costs are relatively small, the impact of the
weakness should be small.
The model’s disease progression is slightly
affected by our data being based on an almost pre-
bronchodilator FEV1 and that the GOLD guidelines
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use postbronchodilator FEV1 to deﬁne severity.
Thus we overestimate the number of severe patients
somewhat. A patient population speciﬁed in the
model will become slightly milder than intended.
Over a 10-year period, the bias should, however, be
very small, and because the shift of patients is sys-
tematic, the overall rate of disease worsening should
be unaffected. Thus, in a comparison of two inter-
ventions, both are affected in the same way
The model is ﬂexible, so that the user can change
a set of variables. This is especially important for
variables such as alpha and beta, where no clear
consensus exists. Consideration of the nature and
existence of this dependence must form part of crit-
ically assessing studies in the model.
The mortality in the model is based on the 10-
year follow-up study of 1457 patients. This is a
rather small material with which to obtain good
mortality estimates, especially when the material
is divided into small subgroups, such as severe
patients. Although this is an arguable weakness, we
do, however, get estimates of mortality from exactly
the same patient material from which we obtain our
estimates of disease progression probabilities,
which is an overall strength of the model.
In the study of exacerbation frequency and dura-
tion, only moderate to severe patients could be
included. No data sets large enough have been
found to measure frequency and duration of exac-
erbations of different severity among patients
within GOLD state I, and some assumptions were
therefore made, as described earlier. Nevertheless,
the outcome of these assumptions was close to pub-
lished sources: the prevalence-weighted exacerba-
tion frequency for our whole COPD population
would be 1.27 per year, compared to ﬁgures from
Anthonisen [22] of 0.1 per month and from Dewan
et al. [23] of 1.2 per year. These ﬁgures include only
moderate to severe patients, which should make
them higher than the ﬁgure in our model. In con-
trast, they also include only moderate to severe
exacerbations, which should make them lower. The
difference in utility values between disease states is
rather small in COPD [29], and therefore the model
is relatively insensitive to changes in QALYs.
We have built a generic model, whose two main
variables, reduction of exacerbation risk and reduc-
tion of disease progression risk, allow evaluation of
a range of interventions. One example is a smoking
cessation program. Our main reason for not using
smoking status as a model variable is lack of sufﬁ-
ciently detailed data. We have data on smoking hab-
its initially and at the 10-year follow-up. In
addition, stratifying the data by smoking habits,
which would be necessary to make smoking habits
a variable in the model, before and after 10 years
would reduce the number of observations in the
strata, affecting the quality of variable estimates.
The smoking habits of our subjects should be rep-
resentative for a COPD population, which gives us
a realistic model. We believe that this is more valu-
able than a model that is able to analyze smoking
habits per se, even though smoking habits are a very
important risk factor in COPD.
Seasonal variation exists in COPD [49,50]. Nev-
ertheless, the model is constructed on an annual
basis, and the shortest assessments that can be made
are 1 year. Hence, this is not an important issue for
the model.
Because Swedish cost data have been used in the
model, its results must be interpreted carefully for
other countries, owing to different prices and
health-care systems. Ideally, the model needs to be
adapted for each country with local cost data. Nev-
ertheless, this is always the case with HE data and
models and not unique to this one. Clinical data
used in the model should be relevant for most indus-
trialized countries.
5. Conclusions
This article has described the development, use, and
outcomes of a computer simulation model for
COPD, which can be used for therapies affecting
FEV1 and/or exacerbation frequency and duration.
Some strengths of the model are its ﬂexibility, allow-
ing an opportunity to compare treatments affecting
different disease mechanisms, to change variable
values, etc., and its use of primary data, validated
against published sources with satisfactory results.
The model has been developed and validated
according to published guidelines.
These analyses show that reducing lung function
decline for COPD patients must be a long-term
strategy compared to reducing the number of exac-
erbations. Here, it was necessary to have a long
term like 30 years, with 10,000 patients and 20%
increase in price, or 20 years with equal prices to
show cost-effectiveness with statistical signiﬁcance
for a treatment that reduces lung function decline.
This shows the potential value of modeling, because
clinical trials of this size and duration would be
unrealistic.
We acknowledge Ola Hössjer and Christin Prütz, Lund
University; Johan Hedbrandt, Linköping University, Swe-
den; and Lars-Göran Carlsson, Ulf Nihlén, Olof Selroos,
and Fredrik Andersson, AstraZeneca R&D Lund, Swe-
A Computer Simulation Model for COPD 163
den, for contributions to the manuscript. Help with data
collection and analysis at St Bartholomew’s Hospital,
London, UK, and the OLIN studies, Luleå, Sweden, is
gratefully acknowledged.
The study was funded by AstraZeneca R&D Lund.
References
1 World Health Organization. World Health Report
[Internet]. Geneva: World Health Organization;
2000. Available from: http://w3.whosea.org/
healthreport/wr2000.htm.
2 Murray CJL, Lopez AD. Evidence-based health
policy—lessons from the Global Burden of Disease
Study. Science 1999;274:740–3.
3 Jansson SA, Andersson F, Borg S, et al. Costs of
COPD in Sweden according to disease severity.
Chest 2002;122:1994–2002.
4 Rutten van Mölken MPMH, Postma MJ, Joore
MA, et al. Current and future medical costs of
asthma and chronic obstructive pulmonary disease
in the Netherlands. Respir Med 1999;93:779–87.
5 Strassels SA, Smith DH, Sullivan SD, Mahajan PS.
The costs of treating COPD in the United States.
Chest 2001;119:344–52.
6 Vestbo J, Rasmussen FV. Respiratory symptoms
and FEV1 as predictors of hospitalization and med-
ication in the following 12 years due to respiratory
disease. Eur Respir J 1989;2:710–5.
7 Andersson F, Borg S, Jansson SA, et al. The costs of
exacerbations in Chronic Obstructive Pulmonary
Disease (COPD). Respir Med 2002;96:700–8.
8 Connors AF, Dawson NV, Thomas C, et al. Out-
comes following acute exacerbation of severe
chronic obstructive lung disease. Am J Respir Crit
Care Med 1996;154:959–67.
9 Niederman MS, McCombs JS, Unger AN, et al.
Treatment cost of acute exacerbations of chronic
bronchitis. Clin Ther 1999;21:576–91.
10 Global Initiative for Chronic Obstructive Lung
Disease. Global Strategy for the Diagnosis, Man-
agement, and Prevention of Chronic Obstructive
Pulmonary Disease. NHLBI/WHO Workshop
report, Publication No. 2701. Bethesda: National
Institutes of Health, National Heart, Lung, and
Blood Institute, 2001 Apr.
11 Miravitlles M, Guerrero T, Mayordomo C, et al.
Factors associated with increased risk of exacerba-
tion and hospital admission in a cohort of ambu-
latory COPD patients: a multiple logistic
regression analysis. Respiration 2000;67:495–501.
12 Seemungal TA, Donaldson GC, Bhowmik A, et al.
Time course and recovery of exacerbations in
patients with chronic obstructive pulmonary dis-
ease. Am J Respir Crit Care Med 2000;161:1608–
13.
13 Donaldson GC, Seemungal TAR, Bhowmik A,
Wedzicha JA. Relationship between exacerbation
frequency and lung function decline in chronic
obstructive pulmonary disease. Thorax 2002;
57:847–52.
14 Pauwels RA, Buist AS, Calverley PM, et al. Global
strategy for the diagnosis, management, and pre-
vention of chronic obstructive pulmonary disease.
NHLBI/WHO Global Initiative for Chronic
Obstructive Pulmonary Disease (GOLD) Work-
shop summary. Am J Respir Crit Care Med
2001;163:1256–76.
15 Lundbäck B, Nyström L, Rosenhall L, Stjernberg
N. Obstructive lung disease in Northern Sweden:
respiratory symptoms assessed in a postal survey.
Eur Respir J 1991;4:257–66.
16 Lundbäck B, Rönmark E, Jönsson E, et al. 10 year
follow-up of the Obstructive Lung Disease in
Northern Sweden study’s (OLIN) ﬁrst cohort. Am
J Respir Crit Care Med 1999;159:134(A).
17 Lundbäck B, Lindberg A, Lindström M, et al. Not
15 but 50% of smokers develop COPD?—Report
from the Obstructive Lung Disease in Northern
Sweden Studies. Respir Med 2003;97:115–22.
18 Statistics Sweden. Statistical Yearbook 1999.
Stockholm: Statistics Sweden, 1999.
19 Price MJ, Hurrell C, Efthimiou J, Medley HV.
Health care costs of treating exacerbations of
chronic obstructive pulmonary disease. Eur Respir
J 1999;14(Suppl 30):S380.
20 Rodriguez-Roisin R. Toward a consensus deﬁni-
tion for COPD exacerbations. Chest 2000;117
(Suppl 2):S398–401.
21 Donaldson GC, Seemungal Wilkinson TM, Wedz-
icha JA. Exacerbation types by COPD severity: risk
of hospitalisation by patients not seeking treat-
ment. European Respiratory Soc Meeting 2003
Vienna. Eur Respir J 2003;22(Suppl 45):S353.
22 Anthonisen NR, Manfreda J, Warren CPW, et al.
Antibiotic therapy in exacerbations of chronic
obstructive pulmonary disease. Ann Intern Med
1987;106:196–204.
23 Dewan NA, Raﬁque S, Kanwar B, et al. Acute
exacerbation of COPD: factors associated with
poor treatment outcome. Chest 2000;117:662–71.
24 Gibson PG, Wlodarczyk JH, Wilson AJ, Sprogis A.
Severe exacerbation of chronic obstructive airway
disease: health resource use in general practice and
hospital. J Qual Clin Pract 1998;18:125–33.
25 National Heart Lung, and Blood Institute. Mor-
bidity and Mortality: 1998 Chartbook on Cardio-
vascular, Lung, and Blood Diseases. Bethesda: US
Department of Health and Human Services, Public
Health Service, National Institutes of Health; 1998
Oct.
26 Mushlin AI, Black ER, Connolly CA, et al. The
necessary length of hospital stay for chronic pul-
monary disease. JAMA 1991;266:80–3.
Borg et al.164
27 Almagro P, Calbo E, Ochoa de Echagüen A, et al.
Mortality after hospitalization for COPD. Chest
2002;121:1441–8.
28 Dolan P. Modeling valuations for EuroQol health
states. Med Care 1997;35:1095–108.
29 Ståhl E, Lindberg A, Rönmark E, et al. The level of
health-related quality of life in patients with COPD
and its dependence on age, gender and disease
severity. Eur Respir J 2001;18(Suppl 33):S184.
30 Andersson F, Borg S, Ståhl E. The impact of exac-
erbations on the asthmatic patient’s preference
scores. J Asthma 2003;40:615–30.
31 Brennan A, Akehurst R. Modelling in health eco-
nomic evaluation, what is its place? What is its
value? Pharmacoeconomics 2000;17:445–59.
32 Hjorth JSU. Computer Intensive Statistical Meth-
ods, Validation, Model Selection and Bootstrap.
London: Chapman & Hall; 1994.
33 Gold MR, Siegel JE, Russel LB, Weinstein MC,
eds., Cost-Effectiveness in Health and Medicine.
New York: Oxford University Press, 1996.
34 National Institute for Clinical Excellence. Guid-
ance for Manufacturers and Sponsors: Technology
Appraisals Process [Internet]. Series No 5. London:
The Institute, 2001 Jun. Available from: http://
www.nice.org.uk/pdf/technicalguidanceformanu
facturersandsponsors.pdf.
35 Kerstjens HA, Rijcken B, Schouten JP, Postma DS.
Decline of FEV1 by age and smoking status: facts,
ﬁgures, and fallacies. Thorax 1997;52:820–7.
36 Scanlon PD, Connett JE, Waller LA, et al. Smoking
cessation and lung function in mild-to-moderate
chronic obstructive pulmonary disease. The Lung
Health Study. Am J Respir Crit Care Med
2000;161:381–90.
37 West R, McNeill A, Raw M. Smoking cessation
guidelines for health professionals: an update.
Thorax 2000;55:987–99.
38 Nishimura K, Tsukino M. Clinical course and
prognosis of patients with chronic obstructive pul-
monary disease. Curr Opin Pulm Med
2000;6:127–32.
39 Anto JM, Vermeire P, Vestbo J, Sunyer J. Epidemi-
ology of chronic obstructive pulmonary disease.
Eur Respir J 2001;17:982–94.
40 Szafranski W, Cukier A, Ramirez A, et al. Efﬁcacy
and safety of budesonide/formoterol in the man-
agement of chronic obstructive pulmonary disease.
Eur Respir J 2003;21:74–81.
41 Pauwels RA, Calverley PMA, Vestbo J, et al.
Reduction of exacerbations with salmeterol/ﬂuti-
casone combination 50/500 mcg bd in the treat-
ment of chronic obstructive pulmonary disease
(COPD). Eur Respir J 2002;20(Suppl 38):S241.
42 Neumann PJ, Hermann MD, Kuntz KM, et al.
Cost-effectiveness of donepezil in the treatment of
mild or moderate Alzheimer’s disease. Neurology
1999;52:1138–45.
43 Weinstein MC, Stason WB. Cost-effectiveness of
coronary artery bypass surgery. Circulation
1982;66:56–66.
44 Mark DB, Hlatky MA, Califf RM, et al. Cost effec-
tiveness of thrombolytic therapy with tissue plas-
minogen activator as compared with streptokinase
for acute myocardial infarction. N Engl J Med
1995;332:1418–24.
45 Edelson JT, Weinstein MC, Tosteson ANA, et al.
Long-term cost-effectiveness of various initial
monotherapies for mild to moderate hypertension.
JAMA 1990;263:407–13.
46 Paltiel AD, Fuhlbrigge AL, Kitch BT, et al. Cost-
effectiveness of inhaled corticosteroids in adults
with mild-to-moderate asthma: results from the
Asthma Policy Model. J Allergy Clin Immunol
2001;108:39–50.
47 Price MJ, Briggs AH. Development of an econom-
ics model to assess the cost effectiveness of asthma
management strategies. Pharmacoeconomics 2002;
20:183–94.
48 Akehurst R, Anderson P, Brazier J, et al. Decision
analytic modeling in the economic evaluation of
health technologies: a consensus statement. Phar-
macoeconomics 2000;17:443–4.
49 Vilkman S, Keistinen T, Tuuponen T, Kivela SL.
Seasonal variation in hospital admissions for
chronic obstructive pulmonary disease in Finland.
Arctic Med Res 1996;55:182–6.
50 de la Iglesia M, Pellicer Vazguez C, Ramos Polledo
V, et al. [Chronic obstructive pulmonary disease
and the seasons of the year.] Arch Bronchoneumol
2000;36:84–9.
51 Craig BA, Sendi PP. Estimation of the transition
matrix of a discrete-time Markov chain. Health
Econ 2002;11:33–42.
52 Borg S, Ericsson Å. A two-dimensional Markov
model with different cycle lengths for a chronic
condition with slow irreversible disease progres-
sion and recurrent periods of severe symptoms.
Value Health 2002;5:221.
Appendix 1
This section gives an overview of the methods for
constructing and evaluating the model. This appen-
dix describes further technical aspects of these
methods.
Introduction to the Two-Dimensional Markov Chain
The two dimensions of our Markov chain are
denoted L for lung function, representing the dis-
ease severity, and E for exacerbation status. At time
t we have a disease severity L(t) and an exacerba-
tion status E(t). The pair L(t), E(t) describes the
health status of the patient at time t.
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The distribution of L(t + 1) depends on L(t),
E(t), and a vector of other variables q (described
below). The distribution of E(t + 1) depends on
L(t), E(t), and q. The vector q contains the
patient’s age, variables speciﬁc to disease assump-
tions, and variables speciﬁc to the intervention
under study.
Transition Probabilities for Disease Severity
This section describes the procedure of estimat-
ing the transition probabilities PL for the disease
progression Markov chain L(t). We enumerate the
state space 1 = mild, 2 = moderate A, 3 = moder-
ate A (regressed), 4 = moderate B, 5 = moderate
B (regressed), 6 = severe, and 7 = death (see
Fig. 2).
The relative frequencies R of transitions were
computed in each of the three age groups from the
data described in section 2.2.1. Living patients with
missing severity classiﬁcation in year 10 (199 sub-
jects) were assumed to belong to the next worse
state, still alive. These R are estimates of the 10-
year transition probabilities. For a shorter cycle
length, we need to rescale the transition probabili-
ties. For a cycle length of t years, we look for a
matrix p that satisﬁes p(10/t) =R. Let us call p the
(10/t)th root of R, for example, if t = 1, the 10th
root. The root of a matrix may not be unique, but
our rather constrained matrix should be uniquely
deﬁned.
Observed transitions to death, p, were used to esti-
mate 10-year all-cause mortality. Using regression of
y = log(p/(1–p)) as a function of disease severity L, a,
and a3, where a is the patient’s age, an equation for
the mortality was estimated. The mortality for a
shorter period of time of t years was obtained as
 for L = i, assuming a constant risk
within the 10-year interval. This approach showed
a good ﬁt to the data, and its shape looks similar to
the risk of death in the general population. Given
these mortality estimates ( ), we used numerical
optimization to ﬁnd the transition probabilities in
each of the three age groups. This gave an estimate
for each age group:  for subjects born 1919 to
1920 and thus 71.5-year-old halfway through the
follow-up period 1986 to 1996, and analogously
 for the other groups. Given any age a,
we interpolate between the two nearest transition
probability matrix (TPM) estimates to obtain the one
for age a, for example, for a between 56.5 and 71.5,
ˆ
/
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To deal with mortality at a very high age, a TPM
with 100% mortality for age 90 is supplied as an
upper limit. Thus, from age 71.5 to 90, the mortal-
ity increases rapidly.
Linear interpolation between two TPMs will
result in a technically valid TPM. Whether this
TPM is relevant as a model component is a question
of validation. We have used this method because it
produces a technically valid TPM in a simple and
intuitive way.
Three aspects inﬂuenced selecting a cycle length.
First, the cycle length must be relevant for the mod-
eled phenomenon. A slow disease may therefore use
long cycles. Second, to be useful in informing short-
term decisions, the model should allow short time
frames. The minimum time frame should be no
longer than 1 year, for example, to inform decisions
that may have a budget impact. Third, the numeri-
cal optimization made it difﬁcult to obtain estimates
for shorter cycles than 1 year. The selected cycle
length for the chain L(t) is therefore 1 year.
The estimated TPMs were validated against the
source data. Certain observed outcomes are not
possible in the model, for example, going from IIB
to I, and some of the larger discrepancies are due to
this. Subdividing by age group and severity class
reduces the number of observed patients, and the
thereby increased uncertainty accounts for most of
the other discrepancies. There then remains mainly
two large discrepancies in subjects born in 1919 to
20: the mortality in state I, which is overestimated
in the model, and the probability of remaining in
state IIA over 10 years, which is underestimated in
the model. The mortality estimate is probably very
uncertain given a rare event in only 1457 patients.
The latter probability is in the model on average
0.12, observed in 78 of 141 patients = 0.55. Apart
from these two large discrepancies and discrepan-
cies owing to the scarce number of observations or
modeling assumptions, the model reproduces the
observed outcomes fairly well. An alternative would
be to make use of a spectral decomposition [51], but
to the best of our knowledge, the disease assump-
tions 1 through 4 cannot be made while using this
method. Spectral decomposition is a method in
closed form, and although this would lessen the
efforts of estimating the TPMs tremendously, it is
hampered by its inability to take into account our
disease assumptions.
Transition Probabilities for Exacerbation Status
We estimated one TPM for the exacerbation status,
for each GOLD class. We enumerate the states as
1 = exacerbation-free, 2 = mild exacerbation, 3 =
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moderate exacerbation, and 4 = severe exacerbation
(see Fig. 3).
The input data are disease severity, exacerbation
frequency for each exacerbation type and mean
duration of each type of exacerbation on individual
patient level. Each individual’s follow-up time is
denoted t (weeks). Its number of mild, moderate
and severe exacerbations are denoted n2, n3, and n4
(exacerbations per week); the corresponding mean
durations are denoted d2, d3, and d4 (weeks) (see
Table 2).
While keeping L ﬁxed, we assume that there is a
stationary distribution for the chain E(t). The fre-
quency of each exacerbation type was estimated for
each GOLD class using the corresponding patients.
The duration of each type of exacerbation was esti-
mated similarly.
The stationary distribution is denoted
. The elements of  are the
proportions of time spent in the states of E(t). We
deﬁne the TPM PE as follows:
where li is the risk of exacerbation and mi represents
the escape probabilities. The stationary distribution
satisﬁes . This gives expressions for  and
the elements of PE: namely,
The exacerbation process is a much more rapid
process than the disease progress. The cycle length
should therefore be much shorter. Judging from the
observed duration of exacerbations and from pub-
lished data [8,9,12,26], a cycle length of 1 week
would be short enough. The methods used to esti-
mate PE do not oppose to a short cycle as in the case
of the L(t). We therefore selected a 1-week cycle.
The use of two different cycle lengths does, how-
ever, add a degree of extra complexity [52], which is
described under “Model Evaluation” section.
Inﬂuence of  Exacerbation Status
In our model, exacerbation status inﬂuences mor-
tality and disease progress according to mechanisms
described in the following subsections. To apply
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changes to mortality and disease progress, the TPM
PL as described above is partitioned into two parts,
one for mortality, , and one for disease progress,
. They satisfy PL = .
Exacerbation Status Inﬂuences Disease Progression
We let exacerbations inﬂuence disease progres-
sion (section 2.2.3). We interpolate between two
extreme scenarios: 1) that disease progress is inde-
pendent of exacerbations and 2) that disease
progress is completely caused by exacerbations, to
obtain a mixture that approximates our belief of
how this works. In case 2, mild, moderate, and
severe exacerbations all affect disease progression
in the same way.
Using a variable a, we interpolate between a= 0
representing (a) and a= 1 representing (b). The
interpolation takes place in the elements of .
We deﬁne the following 1-week probabilities of
progression, p0 when exacerbation-free, and p1,
when struck by exacerbation. The 1-year probability
py is a function of p0 and p1 and the amount of time
spent with exacerbation. This time is given by the
stationary distribution  of E(t). We compute the 1-
week Pw from the yearly rate, pw = 1 – (1 – py)1/52.
When  a= 0,  the  probability  of  progression
is independent of exacerbation status and
p0 = p1 = pw. When a= 1, p0 is 0, and p1 will account
alone for progression. We use a linear relationship,
p0 = (1 – a)pw. Regardless of the value of a, the pro-
gression risk pw must equal the one observed because
a is only our view of an underlying model that pro-
duced that observation. Therefore, pw = p1p0 + (1 –
p1)p1, and this gives p1 = pw(1 – p1(1 – a))/1 – p1).
The 1-year probability of progression, adjusted
for the number of weeks without exacerbation,
w1,  then  becomes  .
This adjustment is made every time the TPM is
used, to let exacerbations inﬂuence progression.
The adjusted py is placed in PLp, and the probability
of staying in the state is adjusted so that the prob-
abilities add up to 1.
Exacerbation Status Affects Mortality To allow
for severe exacerbations inﬂuencing mortality, as
described in section 2.2.4, we interpolate between
1) the mortality is completely independent of exac-
erbation status and 2) the mortality is completely
caused by severe exacerbations. We let b= 0 repre-
sent 1) and b= 1 represent 2).
The weekly mortality mw = 1 – (1 – my)1/52 is com-
puted from the mortality per year, my. It is parti-
tioned into a base mortality m0 and a severe
exacerbation-related mortality m1, according to the
PLm
PLp PLm PLp
PLp
p
~
p p py
w w= - -( ) -( ) -1 1 10 1 52
1 1
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value of beta. When beta is zero, exacerbations do
not affect mortality and m0 = m1 = mw. When beta is
one, m0 is zero, because mortality only occurs in
connection with severe exacerbations. We use the
relationship m0 = (1 – b)mw. Using the stationary
distribution, p, and because the weekly mortality as
observed does not depend on beta, mw = m0(1 –
p4) + m1p4. We obtain an expression for m1 that
depends on beta: m1 = mw(1 – (1 – p4)(1 – b))/p4.
When m0 and m1 thus have been computed,
the annual probability adjusted by the number
of   weeks  of  severe  exacerbation,  ws,  becomes
. This is placed in
, and the diagonal element is adjusted to make
the row add up to 1. For some pi produced by the
PSA evaluation, severe exacerbations are too rare to
account alone for the observed mortality and this
implies an upper limit for beta; that is, there must be
a nonzero base mortality. Thus, once a year each
patient is subjected to a risk of death computed
from his or her experience of severe exacerbations
during the preceding 52 weeks, using beta. In the
ﬁrst year, the preceding 26 weeks are used since
mortality is computed on midyear.
Model Evaluation
The model is evaluated in two steps: ﬁrst variables
are resampled from the various data sets and the
model is evaluated using Monte Carlo simulation.
Second, a bootstrap is used to analyze the popula-
tion results.
The model evaluates a number (selected by the
user) of patients using Monte Carlo simulation.
m m my
w ws s= - -( ) -( )-1 1 10 52 1
PLm
Every patient uses his or her own set of variable rep-
licates estimated from each of the providing data
sets. The disease progress data, the exacerbation
frequency data, the cost-of-illness data, and the cost
of exacerbation data are all random observations
and can be resampled straightforwardly. The QALY
weights for exacerbation-free time are resampled
similarly, and each resample contains one such
weight for each severity degree of COPD. To obtain
the weights for the exacerbation states within each
COPD severity, the resampled exacerbation-free
weight is multiplied by the coefﬁcients shown in
Table 4. In addition, we also sample the initial dis-
ease severity and the start age. The resulting set of
variables is used for simulating one patient. This
procedure is repeated for the desired number N of
patients. The N individual results are then boot-
strapped to estimate conﬁdence intervals for the
patient population, for example, the incremental
cost-effectiveness ratio.
Evaluation Using Two Cycle Lengths Because the
disease severity L(t) chain has a 1-year cycle length
and the exacerbation status E(t) chain has a 1-week
cycle length, the model must be evaluated asynchro-
nously. Each year consists of 52 cycles of E(t). At
midyear, L(t) is evaluated once, informed (see
above) by the events in E(t) since the last update of
L(t). In this way disease progress and mortality
occur midyear, so that we effectively make a half-
cycle correction. This procedure is repeated until
the number of years given by the time frame has
passed in the model.
